Regeneron Pharmaceuticals, Inc.
American biotechnology company headquartered in Tarrytown, New York; originally focused on neurotrophic factors, has expanded into cytokine and tyrosine kinase receptor research, developing treatments for eye diseases, cancer, and infectious diseases.
Clinical Trials
796
385 active
Approvals
13
Total approvals
Agencies
1
Regulatory bodies
Founded
1988
Active, not recruiting
366
46.0%
Available
7
0.9%
Completed
234
29.4%
Enrolling By Invitation
1
0.1%
No Longer Available
3
0.4%
Not yet recruiting
18
2.3%
Recruiting
95
11.9%
Temporarily Not Available
1
0.1%
Terminated
48
6.0%
Unknown
7
0.9%
Withdrawn
16
2.0%
- Both Zenkuda (tarcocimab tedromer) and tabirafusp alfa tedromer met the primary endpoint of noninferiority in best corrected visual acuity versus aflibercept at one year in the phase 3 DAYBREAK study. - Zenkuda achieved its vision endpoint with a p-value of 0.0007, and 54% of patients reached a 24-week dosing interval under strict treat-to-dryness retreatment criteria. - Tabirafusp-ted, an anti-IL-6 and VEGF-trap bispecific, met its vision endpoint at P = .0036 and its anatomical secondary endpoint at P < .0001, with post hoc subgroup analyses planned. - Kodiak plans a three-indication biologics license application for Zenkuda in the fourth quarter of 2026 covering wet AMD, diabetic retinopathy and macular edema following retinal vein occlusion.
- Biohaven's Phase 1 data on BHV-1530, a first-in-class FGFR3-directed antibody-drug conjugate, have been accepted for an oral presentation at the EORTC-NCI-AACR Symposium in Barcelona, November 18-20, 2026. - The ongoing BHV1530-101 study has shown confirmed partial responses in heavily pretreated patients with no dose-limiting toxicities and no FGFR inhibitor-class toxicities such as hyperphosphatemia, nail disorders, stomatitis or retinopathy. - Under a clinical supply agreement with Regeneron, Biohaven has begun enrolling a cohort testing BHV-1530 with cemiplimab (Libtayo) based on preclinical evidence of synergy with anti-PD-1 therapy. - BHV-1530 is designed to target FGFR3 without requiring pathway inhibition, potentially reaching wild-type FGFR3-overexpressing tumors that approved FGFR tyrosine kinase inhibitors do not address.
- The US FDA approved Mirum Pharmaceuticals' once-daily pill zilurgisertib, branded Atebrioz, for patients aged 12 and older with fibrodysplasia ossificans progressiva. - Atebrioz blocks ALK2, a protein abnormally active in most FOP patients that drives bone formation outside the skeleton, at a recommended 100 milligram dose. - Approval was based on a 63-patient study in which Atebrioz significantly reduced new bone formation versus placebo at week 24. - Mirum expects to launch the drug in October, with the company having licensed it from Incyte earlier in 2026 for US$16 million upfront plus milestones and royalties.
- Regeneron Pharmaceuticals has begun a Phase 1 trial of REGN20934, an injectable drug candidate for adults with overweight or obesity. - The randomized, double-blind, placebo-controlled study evaluates single ascending doses, focusing on safety, tolerability and pharmacokinetics. - The trial was first submitted on May 11, 2026, and its ClinicalTrials.gov listing was last updated on September 23, 2026, under NCT07594093. - The early-stage program positions Regeneron in the obesity treatment field alongside established players Novo Nordisk and Eli Lilly.
- Merck's remigromig met the primary endpoint in the Brunello phase 2b/3 trial, showing noninferiority to ranibizumab on best-corrected visual acuity at Week 52. - The trispecific drug agonizes the Wnt signaling pathway by mimicking norrin, offering a non-VEGF mechanism for diabetic macular edema patients. - Remigromig was well tolerated, but proliferative diabetic retinopathy, vitreous hemorrhage and adverse event-related discontinuations occurred more often than with ranibizumab. - Merck acquired remigromig in its $1.3 billion upfront EyeBio takeover and will present the data at the American Academy of Ophthalmology meeting.
- GSK has secured full global rights to Chimagen Biosciences' unnamed trispecific T-cell engager for multiple myeloma in a deal worth up to $750 million. - The preclinical asset is designed to bind T cells while targeting two tumor-associated antigens, aiming for deeper responses and better tolerability than existing engagers. - GSK plans to begin Phase 1 testing in 2027, adding to a myeloma portfolio anchored by the BCMA-directed antibody-drug conjugate Blenrep. - The deal is GSK's second with Chimagen, following the 2024 licensing of the CD19/CD20-targeted T-cell engager CMG1A46 for B-cell malignancies and autoimmune disease.
- Parabolus Medicines' lead candidate zolocatetide, an alpha-helical peptide drug, achieved a 74% objective response rate across 38 desmoid tumor patients who had typically progressed on prior therapy. - The drug targets the beta-catenin/TCF transcription factor complex, implicated in roughly 10% of all cancers and long considered undruggable by small molecules and biologics. - Parabolus raised $770 million in the largest venture-backed biotech IPO on record in 2026, with a Phase 3 desmoid tumor trial planned for H1 2027. - The company's platform uses over 3,000 unnatural amino acids and hundreds of stabilization chemistries to reach flat, pocket-free intracellular protein surfaces.
- The FDA accepted Intellia Therapeutics' Biologics License Application for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema and granted Priority Review with a PDUFA date of March 10, 2027. - The application is supported by global Phase 3 HAELO data showing an 87% reduction in mean monthly attacks versus placebo over the six-month efficacy evaluation period. - The FDA has indicated it does not currently plan to convene an advisory committee, and Intellia aims to launch lonvo-z commercially in the first half of 2027 if approved. - If cleared, lonvo-z would become the world's first in vivo CRISPR-based therapy and the only one-time treatment for HAE, potentially shifting care away from lifelong prophylactic regimens.
- The ANGPTL3 inhibitors market was valued at USD 0.21 billion in 2025 and is projected to reach USD 3.48 billion by 2035, at a 32.4% CAGR. - Monoclonal antibodies led the market with 71% share in 2025, driven by Regeneron's EVKEEZA, the sole FDA-approved ANGPTL3 inhibitor for homozygous familial hypercholesterolemia. - Arrowhead's zodasiran is advancing into Phase III development following positive Phase IIb ARCHES-2 results, positioning RNAi therapeutics as the fastest-growing drug class. - Verve Therapeutics' VERV-201, an in vivo base-editing therapy, is advancing toward potentially one-time, permanent ANGPTL3 reduction for refractory hypercholesterolemia and HoFH.
- A Nature correspondence argues that pre-clinical data interpretation must be grounded in clinical context to avoid misleading translational conclusions. - The exchange involves researchers from The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and The University of Chicago. - The reply clarifies that the Matters Arising discussion concerns the broader clinical implications of findings rather than mechanistic aspects. - Authors disclose extensive industry relationships, including consulting, funding, and patent interests relevant to radiation oncology and cancer research.
